Loading
A phase 1/2 trial of Armored and GPC3-targeted autologous CAR T-cell in hepatocellular carcinoma, run by Shanghai AbelZeta Ltd., now recruiting.
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) is a phase 1/2 interventional study registered as NCT06590246 by Shanghai AbelZeta Ltd., with 121 participants planned, started 2024-09-30 and due to reach its primary completion in 2030-04-30. Interventions recorded: Armored and GPC3-targeted autologous CAR T-cell.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai AbelZeta and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/